Tharimmune Stock Performance
| THAR Stock | 2.26 0.04 1.74% |
Tharimmune has a performance score of 1 on a scale of 0 to 100. The entity has a beta of 0.42, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tharimmune's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tharimmune is expected to be smaller as well. Tharimmune right now has a risk of 10.73%. Please validate Tharimmune value at risk, and the relationship between the jensen alpha and skewness , to decide if Tharimmune will be following its existing price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Tharimmune are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile basic indicators, Tharimmune may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return 0.87 | Five Day Return (13.10) | Year To Date Return (69.35) | Ten Year Return (99.82) | All Time Return (99.82) |
Last Split Factor 1:15 | Last Split Date 2024-05-28 |
1 | Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab | 09/16/2024 |
2 | Acquisition by Appajosyula Sireesh of 5000 shares of Tharimmune at 1.93 subject to Rule 16b-3 | 10/08/2024 |
3 | Tharimmune Announces Upcoming Conference Presentations | 10/25/2024 |
4 | Whats Going On With Tharimmune Shares Wednesday | 10/30/2024 |
5 | Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics | 11/13/2024 |
6 | Short Interest in Tharimmune, Inc. Increases By 2,707.3 | 11/14/2024 |
7 | Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting to Support TH104 for Chronic Pruritus in Chronic Liver Disease | 11/18/2024 |
8 | Tharimmune Abandons Acquisition of Intract Pharma - MarketWatch | 11/21/2024 |
| Begin Period Cash Flow | 6.5 M |
Tharimmune |
Tharimmune Relative Risk vs. Return Landscape
If you would invest 272.00 in Tharimmune on August 30, 2024 and sell it today you would lose (46.00) from holding Tharimmune or give up 16.91% of portfolio value over 90 days. Tharimmune is currently generating 0.1522% in daily expected returns and assumes 10.7307% risk (volatility on return distribution) over the 90 days horizon. In different words, 95% of stocks are less volatile than Tharimmune, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tharimmune Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tharimmune's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tharimmune, and traders can use it to determine the average amount a Tharimmune's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0142
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | THAR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.73 actual daily | 95 95% of assets are less volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Tharimmune is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tharimmune by adding it to a well-diversified portfolio.
Tharimmune Fundamentals Growth
Tharimmune Stock prices reflect investors' perceptions of the future prospects and financial health of Tharimmune, and Tharimmune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tharimmune Stock performance.
| Return On Equity | -4.55 | ||||
| Return On Asset | -1.65 | ||||
| Current Valuation | 408.59 K | ||||
| Shares Outstanding | 1.49 M | ||||
| Price To Book | 1.13 X | ||||
| EBITDA | (9.3 M) | ||||
| Net Income | (9.32 M) | ||||
| Total Debt | 1.82 M | ||||
| Book Value Per Share | 2.35 X | ||||
| Cash Flow From Operations | (7.3 M) | ||||
| Earnings Per Share | 61.01 X | ||||
| Market Capitalization | 3.42 M | ||||
| Total Asset | 10.95 M | ||||
| Retained Earnings | (24.7 M) | ||||
| Working Capital | 9.13 M | ||||
About Tharimmune Performance
Assessing Tharimmune's fundamental ratios provides investors with valuable insights into Tharimmune's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tharimmune is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.85) | (0.89) | |
| Return On Capital Employed | (1.04) | (0.98) | |
| Return On Assets | (0.85) | (0.89) | |
| Return On Equity | (1.02) | (0.97) |
Things to note about Tharimmune performance evaluation
Checking the ongoing alerts about Tharimmune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tharimmune help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tharimmune had very high historical volatility over the last 90 days | |
| Tharimmune has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.32 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tharimmune generates negative cash flow from operations | |
| Tharimmune has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Tharimmune Abandons Acquisition of Intract Pharma - MarketWatch |
- Analyzing Tharimmune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tharimmune's stock is overvalued or undervalued compared to its peers.
- Examining Tharimmune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tharimmune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tharimmune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tharimmune's stock. These opinions can provide insight into Tharimmune's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.